Flywire Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Flywire Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $623.03M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $492.14M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $403.09M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $289.38M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $201.15M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $131.78M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $94.92M | Mar 29, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.90M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($8.57M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($39.35M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($28.09M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($11.11M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | ($20.12M) | Mar 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($7.26M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($21.52M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($30.22M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($13.26M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($15.82M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | ($17.46M) | Mar 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.21M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $66.64M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $62.03M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $50.26M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $31.30M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $24.50M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $15.01M | Mar 29, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.18M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $98.67M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $76.35M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $5.43M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $17.13M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($14.22M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $4.07M | Mar 29, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.35M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $924.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.01M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.35M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.05M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $2.14M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $3.75M | Mar 29, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.12B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.08B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $674.29M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $639.85M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $271.44M | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.14M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $307.68M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $293.61M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $192.38M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $157.64M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $123.03M | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $835.17M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $814.77M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $786.12M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $481.90M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $482.20M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | ($81.76M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | ($75.28M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2018 | ($58.34M) | Mar 29, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $406.51M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $149.56M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $121.65M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $97.77M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $85.84M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $44.65M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $12.92M | Mar 29, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($157.37M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($170.87M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($173.77M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($165.20M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($125.86M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($97.77M) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $330.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $495.24M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $654.61M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $349.18M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $385.36M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $104.05M | Mar 29, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $25.94M | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $24.35M | Mar 29, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 10, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 120.09M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 122.18M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 120.70M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 107.47M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 100.45M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 19.92M | Mar 29, 2022 |